Examining New Therapeutic Pathways in Castration-Resistant Prostate Cancer: A Primer for the Specialty Pharmacist

This activity is supported by an educational grant from Astellas.

Examining New Therapeutic Pathways in Castration-Resistant Prostate Cancer: A Primer for the Specialty Pharmacist

Faculty

Kelly B. Kistler, PharmD

Director of Clinical Services

Avella Specialty Pharmacy

Phoenix, Arizona

Donna M. Smith, PharmD

Director of Clinical Affairs

Avella Specialty Pharmacy

Phoenix, Arizona

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose.

Faculty

Kelly B. Kistler, PharmD, Donna M. Smith, PharmD

Pharmacy Times Office of Continuing Professional Education Planning Staff—Maryjo Dixon, RPh, and Steve Lin, PharmD, RPh

Pharmacy Times Editorial Staff—Kirk McKay and David Allikas

An anonymous peer reviewer was part of the content validation and conflict resolution process. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Objectives

At the conclusion of this educational activity, participants should be able to complete the following:

1. Discuss the epidemiology, pathophysiology, and impact of castration-resistant prostate cancer (CRPC).

2. Examine current management strategies for CRPC and identify emerging therapies.

3. Explore new and future therapeutics for the management of prostate cancer, and specifically CRPC.

4. Identify the role of specialty pharmacists in optimizing outcomes in patients with CRPC.

Target audience: Pharmacists

Type of activity: Knowledge

Release date: December 12, 2013

Expiration date: December 12, 2015

Estimated time to complete activity: 1.5 hour

Fee: This lesson is offered free online at www.pharmacytimes.org. There is a nominal fee of $10.00 for mailed/faxed evaluation and exam forms.

Click here to view this activity.

Pharmacy Times Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEUs) under the ACPE universal activity number 0290-0000-13-169-H01-P. The activity is available for CE credit through December 12, 2015.